Medicines

Thirty-sixth meeting of the Expert Committee on Drug Dependence

The Thirty-sixth meeting of the Expert Committee on Drug Dependence will be held in Geneva from 16 to 20 June 2014.

For more information, please do not hesitate to contact The Secretariat at: ecdd_secretariat@who.int

Note: There will be an open meeting on the morning of the first day. Those interested please register by sending an email to: ecdd_secretariat@who.int

Please note that any expenses incurred as a result of participation in the open session are entirely the responsibility of the attendee.

The documents related to evaluation will be published on this page.

Agenda

1. OPENING OF MEETING

2. PROCEDURAL MATTERS

2.1 Election of chairperson and rapporteur

2.2 Adoption of agenda

3. FOR INFORMATION OF THE COMMITTEE

3.1 Follow up of recommendations made by 35th ECDD

3.2 Work of international bodies concerned with controlled substances

3.3 Strategies for assessing chemically similar substances with similar properties

4. CRITICAL REVIEW OF PSYCHOACTIVE SUBSTANCES

4.1 Tapentadol*

4.2 N-benzylpiperazine (BZP)*

4.3 Gamma-butyrolactone (GBL)*

4.4 1,4-Butanediol (I,4 BD)*

SYNTHETIC CANNABINOIDS

4.5 (1-pentyl-1H -indol-3-yl)-1-naphthalenyl-methanone (JWH-018)@

4.6 (1-buty l- 1H-indol-3-yl)-1-naphthalenyl-methanone (JWH- 073)@

4.7 [1-(5-_fluoropentyl)-1H-indol-3-yl]-1-naphthalenyl-methanone (AM-2201)@

4.8 (1-pentyl-1H -indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)-methanone (UR-144) @

4. 9 1-pentyl-N-tricyclo(3.3.1.13,7)dec-l-yl-1H-indazole-3-carboxamide (APINACA; AKB 48)@

4.10 (4-methoxyphenyl) (1-pentyl-1H -indol-3-yl)-methanone (RCS-4)@

4.11 1-(1-pentyl-1H -indol-3-yl)-2-(2-methoxyphenyl)-ethanone (JWH-250)@

SYNTHETIC CATHINONES

4.12 4 - methylmethcathinone (4-MMC; Mephedrone)@

4.13 3,4-Methylenedioxypyrovalerone(MDPV)@

4.14 bk-MDMA (Methylone )@

4.15 4-Methylethcathinone (4-MEC) @

4.16 4-Fluoromethcathinone (flephedrone; 4-FMC)@

OTHERS

4.17 25 B NBOMe@

4.18 25 C NBOMe@

4.19 25 I NBOMe@

4.20 Alpha-methyltryptamine (AMT) @

4.21 AH-7921@

4.22 Methoxetamine@

4.23 Methiopropamine (MPA) @

5. PRE- REVIEW OF PSYCHOACTIVE SUBSTANCES

5.1 Lisdexamphetamine□

6. UPDATES TO REVIEW CURRENT STATUS

6.1 Tramadol

6.2 Ketamine

7. INFORMATION ON EXEMPTIONS

8. OTHER ISSUES

8.1 Improving data collection and evidence base, in cooperation with other agencies, for substance evaluation

8.2 Planning evaluation of cannabis

8.3 Future agenda

9. ADOPTION OF REPORT

10. CLOSURE OF MEETING

* Pre review recommendation @ CND resolution □ INCB request
Share